In vitro structure–function studies have proposed mechanisms by which SLC30A8 LoF directly affects zinc-mediated insulin storage, processing and secretion [14–25], suggesting a possible path to type 2 diabetes treatment that is independent of weight loss. This evidence concerns the gene SLC30A8 and type 2 diabetes mellitus.